---
title: "Rezolute’s upLIFT Hits Primary Endpoint; Spruce Spins Off CRHX-101 into Adrenyx"
id: "endocrine-news-0-pharma-friday-november-13-2026"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-november-13-2026"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/pharma-friday-november-13-2026/"
published_at: "2026-11-13T17:26:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Rezolute’s upLIFT Hits Primary Endpoint; Spruce Spins Off CRHX-101 into Adrenyx
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-november-13-2026
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/pharma-friday-november-13-2026/)
- **Published At:** 2026-11-13T17:26:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Rezolute announced preliminary positive results from the open-label Phase 3 **upLIFT** study of **ersodetug** in tumor hyperinsulinism, reporting that the study’s primary efficacy endpoint has been achieved based on a November 5 data review. - The primary endpoint is the proportion of participants achieving ≥50% reduction from baseline in glucose infusion rate (**GIR**); statistical success requires the lower bound of the 95% CI to exceed 30% (≥9 responders of 16 planned participants), per the protocol described by the sponsor. - As of the interim evaluation, 13 participants met the responder criterion and 12 of those achieved complete discontinuation of IV glucose; three participants remain in the pivotal period and two have not yet met responder criteria. - One participant discontinued early for hospice care and died from cancer progression; that individual is classified as a non-responder in the primary endpoint analysis. Final statistical results are expected by mid-December 2026. - The upLIFT trial is a single-arm, open-label registrational study enrolling approximately 16 participants with insulinoma or non-islet cell tumors causing uncontrolled hypoglycemia; dosing described in the source is ersodetug 9 mg/kg weekly for 8 weeks as add-on therapy. - Rezolute reported ersodetug has been well tolerated in the pivotal and extension phases with no drug-related safety findings attributed to the antibody, per the company statement. - Spruce Biosciences separated its CRHX-101 (formerly SPR-202) program into a wholly owned subsidiary, Adrenyx Biosciences, intended to focus on endocrinology and development of **CRHX-101**, a monoclonal antibody targeting corticotropin-releasing hormone for classic congenital adrenal hyperplasia (CAH). - Management structure for Adrenyx includes Samir Gharib as CEO; near-term priorities include IND-enabling nonclinical and CMC activities, an IND filing, and initiation of clinical development, according to the company release. - Transaction specifics: contribution of program assets to Adrenyx effective Nov. 6, 2026; Adrenyx closed on $5.0 million of a secured convertible note facility of up to $10.0 million at initial closing; a private placement tied to the Distribution could provide up to $50 million inclusive of note funding. - The Distribution of Adrenyx shares to Spruce stockholders is expected in H1 2027, subject to Spruce board approval, SEC registration effectiveness for Adrenyx, Nasdaq listing approval, and other customary conditions; Spruce’s board had not yet approved the Distribution at the time of the announcement. - Several operational and regulatory uncertainties remain documented: full upLIFT statistical analyses are pending; discussions with FDA are planned in Q1 2027 per Rezolute; the Distribution and financing closings are not assured and may not occur on the anticipated timeline.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/pharma-friday-november-13-2026/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/november-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/pharma-friday-november-13-2026/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Pharma Friday – November 13, 2026 November 13, 2026 Print this article Share this article ![](https://endocrinenews.endocrine.org/wp-content/uploads/pharmaaaaa7.jpg) ##### An _Endocrine News_ roundup of the week’s pharmaceutical news, breakthroughs, and general information. * ## Rezolute Announces Positive Results from the Phase 3 Uplift Study in Tumor Hyperinsulinism On November 13, **[Rezolute](https://rezolutebio.com/)** , a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary results from a November 5 data evaluation. The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia. To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants. To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose. Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion. As previously reported, one participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression. This participant has been classified as a non-responder for purposes of the primary endpoint. Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026. ![](https://endocrinenews.endocrine.org/wp-content/uploads/Rezolute-Logo.jpg) “We are thrilled with this outcome and what it means for individuals living with tumor hyperinsulinism,” said Nevan Charles Elam, Founder and Chief Executive Officer of Rezolute. “Notably, these results substantially mirror the powerful outcomes that we have observed over the last few years in our expanded access program. We believe that we are well positioned to advance both congenital HI and tumor HI into the approval process next year and we look forward to discussions with FDA in the first quarter of 2027.” The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas). Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug. **About upLIFT** The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI). Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care. Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension. The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in GIR, a measure of intravenous glucose dependency for underlying hypoglycemia. Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life. **About Tumor Hyperinsulinism** Tumor hyperinsulinism (HI) is a rare disease that may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia because of over-activation of the insulin receptor. Insulinomas are the most common type of ICT and cause hypoglycemia via the overproduction of insulin. A variety of different NICTs, including hepatocellular carcinoma and soft tissue malignancies (e.g. sarcomas), can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances, such as variants of IGF-2, that bind to and activate the insulin receptor. With high morbidity and mortality rates within tumor HI, there remains a significant unmet need for new therapies directed at hypoglycemia treatment. Ersodetug has shown real-world benefit in patients with insulinoma and NICTs. **About Ersodetug** Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. ## **Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences** On Nov. 9, Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has separated the company’s CRHX-101 (formerly SPR-202) program into Adrenyx Biosciences, Inc. (“Adrenyx”), a newly formed wholly-owned subsidiary of Spruce that will operate as a dedicated endocrinology company (the “Separation”). Spruce currently intends to distribute all of the outstanding shares of Adrenyx common stock to Spruce stockholders on a pro rata basis (the “Distribution”), in a transaction expected to result in two independent, publicly traded companies. Samir Gharib, who currently serves as President and Chief Financial Officer of Spruce Biosciences, is the President and Chief Executive Officer of Adrenyx and is expected to continue in that role following the Distribution. Mr. Gharib will also continue to serve in his role as President and Chief Financial Officer of Spruce Biosciences. ![](https://endocrinenews.endocrine.org/wp-content/uploads/logo-spruce-header-min.jpg) “The Separation is designed to enable each company to pursue its distinct strategic path with a focused team, a dedicated capital structure and a clearer value proposition for investors,” said Javier Szwarcberg, MD, MPH, Chief Executive Officer of Spruce Biosciences. “Spruce will remain focused on neurological disorders and working to deliver TA-ERT to children and families living with MPS IIIB, including its planned BLA submission in December 2026 and preparation for a potential U.S. commercial launch next year, if approved.” “Separating CRHX-101 into Adrenyx positions a differentiated, late preclinical-stage program to be advanced by a dedicated team with the resources and time horizon the opportunity deserves,” said Samir Gharib, President and Chief Executive Officer of Adrenyx. “CRHX-101 is being developed to address what has long been the central limitation of CAH care: the tradeoff between controlling the disease and limiting the burden of treatment. By targeting an upstream driver of adrenal androgen excess, CRHX-101 is designed with the goal of delivering durable disease control and reducing the daily demands of lifelong disease management, which includes chronic high-dose steroid exposure, potentially leading to growth impairment, bone loss, metabolic complications, and Cushingoid features. Guided by a team with a legacy in CAH development, Adrenyx is being purpose-built to continue advancing this work on behalf of the patient community.” ### **Separation of CRHX-101 Program into Adrenyx Biosciences** Upon completion of the Distribution, Adrenyx will be an independent, publicly traded, late preclinical-stage biotechnology company focused on the development of CRHX-101, a monoclonal antibody designed to selectively neutralize corticotropin-releasing hormone (“CRH”), the upstream driver of adrenal androgen excess in classic CAH. By acting at the top of the hormone signaling cascade, CRHX-101 is intended to achieve durable, upstream disease control with the potential to reduce the compromises that have long defined CAH treatment. Adrenyx’s near-term priorities include completion of IND-enabling nonclinical and chemistry, manufacturing and controls activities, the filing of an Investigational New Drug application for CRHX-101 with the U.S. Food and Drug Administration (the “FDA”), and initiation of a clinical program thereafter. Following the Distribution, Spruce will continue to operate as a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, with TA-ERT for the treatment of MPS IIIB as its lead program. Spruce will continue to be led by Javier Szwarcberg, M.D., M.P.H., and the balance of its existing executive and clinical leadership team, including Mr. Gharib, is expected to remain with Spruce. Adrenyx is expected to be led by: * Samir Gharib, as President and Chief Executive Officer; * Kirk Ways, MD, PhD, as Chief Medical Officer; * Patrick Gearing, PhD, as Head of Chemistry, Manufacturing and Controls; and * Meghan Bowler, PhD, as Project Team Leader. Members of the board of directors and additional members of the management team will be announced at a later date. Spruce’s board of directors has not yet approved the Distribution or set a record date for the Distribution. Prior to the Distribution, Adrenyx will operate as a controlled subsidiary of Spruce. ### **Transaction Terms** On November 6, 2026, Spruce and Adrenyx entered into a separation and distribution agreement and a transition services agreement. Pursuant to these agreements, Spruce contributed to Adrenyx assets and liabilities relating to the CRHX-101 program effective as of November 6, 2026, and Spruce agreed to provide specified services to Adrenyx for a period of up to 12 months following the completion of the Distribution, subject to extension, compensated by Adrenyx at Spruce’s cost without markup. Also on November 6, 2026, Adrenyx entered into a secured convertible note purchase agreement with a leading institutional biotechnology investor, pursuant to which Adrenyx may issue secured convertible promissory notes in an aggregate principal amount of up to $10.0 million, of which $5.0 million aggregate principal amount was issued at the initial closing on November 6, 2026. Issuance of the remaining notes in subsequent closings is subject to certain terms and conditions set forth in the secured convertible note purchase agreement, including consent of the investor. Adrenyx is required to use the proceeds of these notes to develop and commercialize the CRHX-101 program and for its other general corporate purposes, and Spruce is not permitted to use any of the proceeds to fund its own operations. A private placement of Adrenyx equity securities to institutional investors is expected to be completed in connection with the Distribution to provide further financing to Adrenyx, with up to $50 million funded by the convertible notes investor, inclusive of their note funding; further details will be announced at or prior to the closing of the private placement. The Distribution is expected to be completed in the first half of 2027, subject to the satisfaction or waiver of certain conditions set forth in the separation and distribution agreement, including the approval of the Distribution by Spruce’s board of directors, the effectiveness of a registration statement to be filed by Adrenyx with the U.S. Securities and Exchange Commission (“SEC”) and the approval of the listing of Adrenyx common stock on Nasdaq. Approval by Spruce stockholders is not required as a condition to the consummation of the Distribution. The Distribution is expected to be a taxable transaction for U.S. federal income tax purposes. There can be no assurance that the Distribution, any subsequent closing of Adrenyx notes or the private placement will be completed on the anticipated timeline, on the anticipated terms, or at all. ## New Data at A
## Related Clinical Research

- [Amylyx Presents Avexitide Results; MiniMed Launches Tubeless Insulin Pump](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-november-21-2026.md)
- [Advances in Diabetes Technology: Digital Platforms Beyond Continuous Glucose Monitoring](https://medichelpline.com/clinical-feed/endocrine-news-0-beyond-the-sensor-enhancing-diabetes-technology.md)
- [Myeloid mDIC (SLC25A10) Loss Reprograms Adipose Macrophages and Improves Metabolism in Obesity](https://medichelpline.com/clinical-feed/biorxiv-11-myeloid-mdic-deficiency-remodels-adipose-macrophages-to-an-efferocytosis.md)
- [Later bedtimes and late eating tied to higher metabolic syndrome risk](https://medichelpline.com/clinical-feed/medical-news-today-0-eating-and-sleeping-later-associated-with-increased-health-risks.md)
- [Genomic SEM identifies shared genetic architecture and candidate genes for insulin resistance–rela](https://medichelpline.com/clinical-feed/plos-one-18-integrative-genomic-sem-analysis-of-shared-genetic-architecture-and-candidate.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.